Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Ovarian Neoplasms 3Fallopian Tube Neoplasms 3Uterine Neoplasms 2Prostatic Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Lymphoma 2Hematologic Neoplasms 2Carcinoma, Renal Cell 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Muscle Invasive Bladder Cancer 1Meningeal Carcinomatosis 1Melanoma 1Lung Neoplasms 1Glioma 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Carcinoma 1Brenner Tumor 1

Interventions

Carboplatin 25Paclitaxel 24pembrolizumab 22Cyclophosphamide 14Gemcitabine 10Capecitabine 10Doxorubicin 9Specimen Handling 8Nivolumab 8Taxes 7Magnetic Resonance Spectroscopy 7sacituzumab govitecan 6olaparib 6Cisplatin 6eribulin 5durvalumab 5atezolizumab 5Radiotherapy 5Albumin-Bound Paclitaxel 5130-nm albumin-bound paclitaxel 5capivasertib 4Epirubicin 4Docetaxel 4Biopsy 4niraparib 3Vinorelbine 3Radiation 3Fulvestrant 3Blood Specimen Collection 3trastuzumab deruxtecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Triple Negative Breast Neoplasms × adavosertib × Clear all
NCT03330847 2026-03-10

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

AstraZeneca

Phase 2 Active not recruiting
273 enrolled 22 charts
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡